PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ccLink to Publisher's site
 
Cell Cycle. 2016; 15(6): 819–826.
Published online 2016 March 30. doi:  10.1080/15384101.2016.1148836
PMCID: PMC4845948

Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors

ABSTRACT

Despite state of the art cancer diagnostics and therapies offered in clinic, prostate cancer (PCa) remains the second leading cause of cancer-related deaths. Hence, more robust therapeutic/preventive regimes are required to combat this lethal disease. In the current study, we have tested the efficacy of Andrographolide (AG), a bioactive diterpenoid isolated from Andrographis paniculata, against PCa. This natural agent selectively affects PCa cell viability in a dose and time-dependent manner, without affecting primary prostate epithelial cells. Furthermore, AG showed differential effect on cell cycle phases in LNCaP, C4-2b and PC3 cells compared to retinoblastoma protein (RB−/−) and CDKN2A lacking DU-145 cells. G2/M transition was blocked in LNCaP, C4-2b and PC3 after AG treatment whereas DU-145 cells failed to transit G1/S phase. This difference was primarily due to differential activation of cell cycle regulators in these cell lines. Levels of cyclin A2 after AG treatment increased in all PCa cells line. Cyclin B1 levels increased in LNCaP and PC3, decreased in C4-2b and showed no difference in DU-145 cells after AG treatment. AG decreased cyclin E2 levels only in PC3 and DU-145 cells. It also altered Rb, H3, Wee1 and CDC2 phosphorylation in PCa cells. Intriguingly, AG reduced cell viability and the ability of PCa cells to migrate via modulating CXCL11 and CXCR3 and CXCR7 expression. The significant impact of AG on cellular and molecular processes involved in PCa progression suggests its potential use as a therapeutic and/or preventive agent for PCa.

KEYWORDS: Andrographolide, Cell cycle, Cyclins, CXCR3, CXCR7, CXCL11, chemokine, chemokine receptor and prostate cancer

Introduction

Elucidating the mechanisms and developing therapies against prostate cancer (PCa) has been a long-standing interest for many researchers. Currently offered chemotherapeutic regime for hormone refractory PCa are often associated with hepatotoxicity and renal failure. Natural compounds are gaining popularity in the ‘war on cancer’ over conventional chemotherapies due to dearth of effective therapies without side effects. Compounds obtained from microbial and plant sources can be less toxic and more beneficial than conventional anti-cancer agents. As a result, many of these agents are in clinical trials; though certain limitations are associated with them.1,2 A major limitation of natural compounds is their poor bioavailability. However, Andrographolide (AG), a diterpenoid extracted from Andrographis paniculata, has an advantage over other natural agents due to its better absorption and hepatoprotective effects. Independent pharmacokinetic studies showed that 90% of orally administered AG is absorbed in the blood and 40% in tissues and cells.3,4

AG functions mainly by manipulating cell cycle and cytokine signaling. Studies have shown that it inhibits NF-kB and reduces pro-inflammatory cytokines IL-2, IL-6, TNF-α and IFN-γ in PCa.5,6 Role of these cytokines on host and cancer cells during disease progression has been well proven. Cytokines mediated signals can cross talk with chemokines and multiple chemokine-receptors are shown to be associated with tumor progression and metastasis.7-17 Additionally, cell cycle regulation is governed by calcium flux, which in turn is altered by chemokine signaling. In this manuscript we have presented evidence that AG exerts its anticancer effects by modulating cell cycle as well as chemokine receptors (CXCR3 and CXCR7) and their common ligand CXCL11 in PCa cells.

Results

AG decreases prostate cancer cell viability

Effect of AG was tested on PCa cells (LNCaP, C4-2b, PC3 and DU-145 cell lines) differing in androgen dependence and metastatic potential. Normal prostatic epithelial cells (PrEC) were used as control. Cell viability of PCa cell lines with or without AG treatment using MTT assay displayed differential susceptibility, IC50 ~20 µM (PC3 and DU-145 cells) and ~50 µM (LNCaP and C4-2b cells), to AG compared to untreated cells; whereas the effect of AG on PrEC cells was minimal (Fig. 1).

Figure 1.
AG induces dose dependent death in PCa cell lines. Reduction in cell viability after AG treatment was assayed using MTT. Line graph represents 48 hr treatment data. Primary prostate epithelial cells were less sensitive to AG.

AG affects cell cycle distribution by modulating the activation status of cell cycle regulators

Cell cycle progression is facilitated and governed by an extensive cascade of cyclins and cyclin-dependent kinases and phosphatases. AG treatment showed no significant change in cyclin E2 levels in LNCaP or C4-2b cells. However, a decrease in cyclin E2 levels was observed in PC3 and DU-145 cells, 24 hr following AG treatment (Fig. 2). Cyclin A2 was higher in LNCaP, C4-2b and PC3 cells after 6 hr AG treatment, which was sustained till 24 hr in C4-2b and PC3. However, in DU145 cells cyclin A2 levels decreased after 6 hr AG treatment and marginal increase was observed after 24 hr.

Figure 2.
Effect of AG on the status of cell cycle regulators in PCa cell lines. 20μM AG modulates phosphorylation of cell cycle checkpoints in PCa cells: LNCaP and C4-2b and, PC3 and DU-145. Protein samples were collected at 6 and 24 hr after AG ...

On the other hand, Cyclin B1 increased in LNCaP and PC3 after addition of AG but C4-2b cells showed a reduction in cyclin B1 levels after 24 hr and no change was observed in DU-145.

Reduction in phosphorylation of (Ser807/811 and Ser795) Rb (retinoblastoma protein) in LNCaP, C4-2b and PC3 was noted after AG treatment. A reduction in CDC2 phosphorylation (Tyr15) was observed in all the 4 PCa cell lines 24 hr after AG treatment, with C4-2b cells showing reduction in CDC2 phosphorylation as early as 6 hr. Phosphorylation of H3 (Ser10, Ser28, and Thr11) was drastically reduced in C4-2b cells as early as 6 hr but increased in PC3 cells after 24 hr AG treatment. However, AG had no effect on the phosphorylation status of H3 in LNCaP and only negligible phosphorylation of H3 was detected in DU-145 cells. Phosphorylated (S642) Wee1 was reduced in LNCaP cells after 24 hr of AG treatment, while reduction in Wee1 phosphorylation in C4-2b cells was observed after 6 hr. Interestingly, PC3 cells showed an increase in the phosphorylation of Wee1 at 6 hr, but this increase was diminished by 24 hr of AG treatment. No such change was observed in DU-145 cells (Fig. 2).

The level of cyclin dependent kinase inhibitor-p21 was determined in all PCa cell lines. Following AG treatment, a reduction in p21 was observed in LNCaP, C4-2b and DU-145 cells and this reduction was remarkable in DU-145 compared to LNCaP and C4-2b, but no change was observed in PC3 cells that express very low levels of p21.

To further understand the significance of these changes in cell cycle regulators, we studied the impact of AG on PCa cell cycle. Distribution of PCa cells in cell cycle phases was affected after 24 hr AG treatment (Fig. 3). Specifically, LNCaP (G2%: 9.19 to13.9%), C4-2b (G2%: 11.4 to12.7%) and PC3 (G2%: 10.4 to 12.9%) cells were stalled in G2/M phase, while DU-145 cells showed G1 phase arrest (G1%: 40 to 57.4%). Consequently, G1/G2 ratio varied significantly after AG treatment (Table 1).

Figure 3.
AG changes the cell cycle phase distribution of PCa cells. AG arrests LNCaP, C4-2b and PC3 cells in G2/M phase while DU-145 in G1 phase.
Table 1.
Cell cycle after AG treatment. Table represents changes in the percent cell distribution in different phases of cell cycle. AG blocks the G2/M transition in LNCaP, C4-2b and PC3 whereas DU-145 cells fail to transit G1/S phase.

AG modulates chemokine expression in PCa cells

Multiple chemokines are involved in dissemination and homing of many cancer including PCa.10-17 We found that CXCR3 expression in LNCaP cells was decreased after 6 hr of AG treatment, but this suppressive effect was short lived and the receptor expression recovered after 24 hr. In case of PC3 and DU-145 cells, reduced expression of CXCR3 was maintained from 6 to 24 hr after AG treatment. CXCR7 also showed similar expression patterns following AG treatment (Fig. 4) as CXCR3 and both share a common ligand-CXCL11, although the reduction of CXCR7 expression was not as prominent as CXCR3 in LNCaP cells. The reduction of CXCR3 and CXCR7 expression after AG treatment corresponded with an increase in expression of CXCL11 in PC3 and DU-145 cells, but CXCL11 was below detection in LNCaP cells suggesting a different regulatory mechanism of chemokine receptor(s) expression in hormone-responsive LNCaP (Fig. 4).

Figure 4.
AG affects chemokine receptor expression in PCa cells. Treatment with AG significantly reduced levels of CXCR3 and CXCR7 while CXCL11 is induced after 24 hr as assessed by western blot.

AG affects PCa cells viability and migration via CXCL11-CXCR3/7 axes

Cell viability was determined after blocking CXCR3/CXCR7 with monoclonal antibody to understand the significance of AG mediated reduction in these chemokine receptors (Fig. 5). Growth of the PCa cells was significantly stunted after receptor blockade but stimulation of these receptors with CXCL11 did not show a significant effect on growth of PCa cell line. Migratory potential of PCa cells when treated with suboptimal dose of AG (20 uM - LNCaP and C4-2b and 7.5uM - PC3 and DU-145, respectively) was drastically reduced. There was no significant change in AG induced inhibition of PCa cell migration when CXCL11 was used as chemo-attractant. Blocking CXCR3 prior to AG treatment increased the migration of LNCaP cells toward CXCL11 (Fig. 6). As expected, the migration of control cells significantly decreased after CXCR3 blocking.

Figure 5.
CXCL11-CXCR3/7 axes affects viability of PCa cells. Blocking of CXCR3 or CXCR7 reduces the viability of PCa cells. Addition of CXCL11 also affects PCa cell viability. *, p value < 0.05; **, p value< 0.01 and ***, p value< 0.001 ...
Figure 6.
AG affects PCa cell migration via CXCR3-CXCL11 axis. Migration of all the 4 cell lines is drastically attenuated after AG treatment. Addition of CXCL11 increases while blocking of CXCR3 stunts migration of all the 4 cell lines at varied extent. AG treated ...

Discussion

Failure to exit the mitotic phase or a derailed cell division cycle can culminate into the development of neoplasia; therefore, most anti-cancer drugs target cell cycle. Unfortunately, these cancer drugs are limited due to their off-target effects and corresponding toxicities. To address this issue, we have used a natural compound, AG (Andrographolide) that has anti-inflammatory and anti-tumor activity in this study.5,6 Unlike other natural compounds, this bioactive constituent is readily absorbed in vivo3,4 and have protective effects on liver and kidney.18,19 We assessed the efficacy of AG on different PCa cell lines. LNCaP and C4-2b cells are less sensitive to this compound, as compared to PC3 and DU-145 cells. Thus, AG has potential to target PCa cells, which are aggressive in nature. Our results suggest that AG affects PCa cell growth by multiple mechanisms and more importantly, it could be effectively used in advanced PCa, which is less responsive to chemotherapies.

AG affects PCa cells survival by arresting their cell cycle.5 We show that it imposes this effect by modulating specific cyclin and cyclin dependent kinase activities. This compound reduces the expression of cyclin D1 and CDK4 and hence the formation of active cyclin D1/CDK4 complex in human colorectal carcinoma Lovo cells.20 AG also induces p27 while decreasing CDK4 expression in rheumatoid arthritis fibroblast-like synoviocytes.21 Our data show effect of AG on Cyclin E2, a G1 phase cyclin that is expressed in a tissue specific manner and at very low levels in non-neoplastic cells. Tumor-derived cells express significantly high levels of cyclin E2.22 Our data show a decrease in cyclin E2 expression by PC3 and DU-145 cells, after AG treatment. Cyclin E2 was not significantly modulated in LNCaP and C4-2b cells. Similar effect of AG was found in lung tumor of VEGF – A165 transgenic mice.23 Cyclin E2 associates with and activates CDK2 to promote phosphorylation of Rb, to drive cells from G1 to S phase. A reduction in cyclin E2 would presumably reduce Rb phosphorylation. We show that LNCaP, C4-2b and PC3 cells treated with AG have reduced Rb phosphorylation (Ser807/811 and Ser795). Hypo-phosphorylated Rb following AG treatment would support sequesteration of E2F, which in its free state enables progression to S phase by upregulating cyclin E and cyclin A expression. AG could also affect expression and activity of cyclin E and CDK2 via GSK3-β and c-Myc.24,25

Cyclin A regulates cell cycle at multiple stages by interacting with CDC2 and CDK2. The cyclin A/CDK2 complex is required for DNA replication and subsequent S phase. The availability of cyclin A/ CDC2 is a rate-limiting step for mitosis. It is apparent that AG treatment increased cyclin A2 in PCa cells, although at different time points. Free-E2F induced expression and degradation during prometaphase are 2 factors regulating cyclin A2 levels.26 Based on Rb phosphorylation status, it is the degradation of cyclin A2 that is affected by AG. Degradation of cyclin A2 during pro-metaphase is required for mitotic exit. Hence, increased cyclin A2 observed in PCa cells after AG treatment implicates that these cells will undergo mitotic arrest.

Cyclin A complexes with CDK to phosphorylate CDC25 and consequently activate cyclin B-CDC2 complex. Cyclin B1 levels increase after AG treatment in LNCaP and PC3 cells and decrease in C4-2b cells. DU-145 cells show no change in their cyclin B1 levels after AG treatment. Studies have shown overexpression of cyclin B1 in various cancers, including prostate27 and it is a poor prognostic marker.28 Nevertheless, high levels of cyclin B1 during early stages of cancer boost immune system by promoting T cells and antibody production.29 Moreover, nuclear accumulation of cyclin B1 is required for mitosis. AG induced cyclin B1 in PC3 and LNCaP cells could be restricted to the cytoplasmic fraction depending on its phosphorylation status.30 Besides, our data also show that AG reduces expression/phosphorylation of CDC2, which is sufficient to stop mitotic division leading to G2/M arrest.31 Similar findings have been reported by others using human glioblastoma cells.32 Since anaphase-promoting complex degrades cyclin B1 before cell cycle proceeds, increased levels of cyclin B1 observed in LNCaP and PC3 cells, may be due to a halt at ‘pre’ anaphase stage of mitosis. Thus AG affects cell cycle in LNCaP and C4-2b cells mainly via cyclin A2 and B1 whereas in DU-145 cells cyclin E related regulation is more important. In PC3 cells, AG modulates all 3 cyclins.

Additionally, it is known that cyclin A2 and B1 expression positively correlates with H3 phosphorylation that characterizes chromatin condensation during initiation of mitosis.33,34 AG treatment increased H3 (Ser10, Ser28, and Thr11) phosphorylation in LNCaP and PC3 cells, but completely abolished it in C4-2b cells, which corresponded well with cyclin B1 levels in these cells. Wee1 (kinase) activity also regulates cell cycle by phosphorylating H3 and CDC2. Phosphorylation of Wee1 at S642 deactivates it. AG treatment affected Wee1 phosphorylation status in all the 4 cell lines to varied extent. Neither H3 nor CDC2 phosphorylation status correlated with Wee1 phosphorylation status. This could be the consequence of AG induced increase in another phosphatase like PP2A.35 Our unpublished data shows AG affects Chk2 that could inhibit CDC25 family of protein, which in turn dephosphorylate (Wee1 phosphorylated) CDC2.36-38 Activity of these phosphatases and kinases synchronize the firing of replication origin during S phase, which consequently controls the length of S phase.39

Shortening of S phase could also be due to reduced p21 as low p21 levels are required for release from S phase arrest and cells with high p21 move slowly through S phase. Expression levels of p21 are low in PC3 cells and AG did not affect p21. Levels of p21 are reduced in all other PCa cells after AG treatment, remarkably so in mutated p53 bearing DU-145 cells. Decrease in p21 levels could be a consequence of the effect of AG on Hsp90, which is important for p21 protein stability.40 AG is reported to interfere with the binding of hsp90 with other proteins and promote Hsp90 degradation.41,42 On the other hand, this effect of AG on p21 levels could be due to its enhanced degradation by other factors.43 In either case, it is clear that despite low levels of p21 AG is capable of arresting PCa cell cycle by affecting the cyclin/CDK complexes.

All cells show G2 phase arrest after AG treatment, except DU-145 cells, which lacks CDKN2A locus and hence have no p16 (p16INK4a) or p14arf. These proteins lead to G1 phase arrest by influencing CDK4-cyclin D and CDK6-cyclin D complexes. These cells also lack Rb1. Absence of all these proteins could lead to the G1 phase arrest in these cells instead of G2 as seen in other PCa cells.

We elucidated the effect of AG on chemokine receptors expressed by PCa cells. CXCR3 was significantly reduced after AG treatment; CXCR7 was also affected. Aksoy et al. 44 demonstrated that surface expression of CXC chemokine receptor CXCR3 is confined to S + G2/M in human airway epithelial cells; however, we could not detect any such cell cycle phase specific expression of CXCR3 (data not shown). CXCL-9, −10 and −11 are 3 non-redundant ligands that bind to CXCR3. Of these, CXCL11 has higher affinity toward CXCR3 and also binds to CXCR7. Interestingly, AG induces CXCL11 expression in PC3 and DU-145 cells. The reduction in CXCR3 expression could be due to AG induced expression of CXCL11 in AR-independent PCa cell lines as observed in other study.44 AG is known to modulate, IFN-α, -β and –γ, cytokines which induce CXCL11.45 Hence, increased CXCL11 expression in AG-treated cells could be due to its effect on IFNs. In addition to this, imitating AG effect by blocking of CXCR3, CXCR7 or addition of CXCL11 in PCa cells reduces proliferation. Neutralizing CXCL11 in AG-treated cells significantly increased the proliferation of PC3 cells (unpublished data). This implicates that AG affects proliferation in other PCa cells via factors other than CXCL11. Migration of all 4 PCa cells was drastically hindered after treatment with sub-lethal doses of AG. As expected, blocking CXCR3 significantly decreased migration of PCa cells toward CXCL11. But, this effect was not seen in AG treated cells as AG treatment itself reduces CXCR3 expression. When CXCR3 was blocked in LNCaP cells prior to AG treatment migration under CXCL11 gradient was higher than only AG treated LNCaP cells. This result implies that in LNCaP cells, where CXCR7 was not significantly affected by AG, CXCR7 compensates for blocked CXCR3. All this together indicates that CXCL11 induced migration is governed by CXCR3 (with an exception of LNCaP) in PCa cells whereas CXCR7 is important for viability. These results show that AG hinders key mechanisms involved in cancer progression by interfering with CXCR3/7-CXCL11 axes.

In conclusion, ability of AG to impede cancer growth by impacting key cell cycle regulators and chemokines, which are otherwise difficult to target due to their crucial physiological role, rationalizes its application as a potent therapeutic/preventive agent.

Materials and methods

Chemicals, cell lines and cell culture

Andrographolide was purchased from LKT laboratories. PC3 and LNCaP cell lines were obtained from the ATCC (Manassas, VA, USA). Normal prostate epithelial cells (PrEC) were obtained from Clonetics-Biowhittaker (Walkersville, MD, USA) and cultured in PrEMB medium (Clonetics-Biowhittaker). PC3 cells were cultured at 37°C with 5% CO2 in F12 K medium with 2 mM L-glutamine and with 10% fetal bovine serum (FBS) (Sigma, St Louis, MO, USA). LNCaP, C4-2b and DU-145 cells were cultured in RPMI-1640 with 10% FBS. All the experiments were carried out in presence of 1% FBS containing respective medium unless specified.

Flow cytometry

For cell cycle analysis, PCa cells (1 × 106) treated with and without AG were washed thrice with fluorescence-activated cell-sorting (FACS) buffer (PBS supplemented with 2% fetal bovine serum). Cells were then stained with propidium iodide (Cell signaling) as per manufacturer's instruction. Cells were analyzed by flow cytometry using a Guava easy cyte flow cytometer (Millipore) and flow Jo 10.0.6 software (Treestar Inc.).

Viability assay

PCa cells were seeded at a density of 2 × 104/100ul/well in 96 well plates. Next day, keeping the volume constant, cells were treated with different concentration (0–100μM) of AG. Cell proliferation was assessed 24, 48 and 72 hr using MTT assay.46 Briefly, MTT (20 μL of 5 mg/ml in PBS) was added in each well and plate was incubated at 37°C for 3 hr. Resultant formazan crystals were dissolved in 100 μL of DMSO and absorbance was measured at 570 nm. To validate the data the experiment was repeated 3 times.

Migration assay

Migration studies were performed using BD Biocoat migration chambers (Becton-Dickson Labware). Inserts were activated with serum free DMEM for 2 hr at 37°C with 5% CO2. Next, 0.5 × 105 cells were added to the top chamber of inserts and 100ng/ml CXCL11 (Peprotech, NJ) was added as chemo-attractant in the bottom chamber. To determine if the migration of PCa cells is mediated specifically by CXCR3-CXCL11 interaction, cells pre-incubated with 1.0 μg/ml anti-CXCR3 antibody (R&D Systems) were added to the top chamber in one well of Matrigel or control inserts and allowed to migrate under chemotactic gradient of CXCL11 for overnight at 37°C and 5% CO2. After incubation, non-migrating cells on the upper surface of the membrane were removed with a cotton swab. Cells at the bottom surface of the insert were fixed with 100% methanol for 2 min, stained for 2 min with 1% Toluidine blue O in 1% Borax (Fisher Scientific), and rinsed twice with de-ionized water. Migrated cells were counted by microscopy at 40X magnification. All experiments were repeated 3 times to validate the results.

Statistics

Results of viability and migration assays were analyzed by one-way ANOVA. Values were considered significantly different at a level of 0.05.

Abbreviations

AG
Andrographolide
PCa
Prostate Cancer

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Funding

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R21CA169716 and in part by U01CA179701, SC1CA180212 and Morehouse School of medicine FACS core. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

[1] Saklani A, Kutty SK. Plant-derived compounds in clinical trials. Drug Discov Today 2008; 13:161-71; PMID:18275914; http://dx.doi.org/10.1016/j.drudis.2007.10.010 [PubMed] [Cross Ref]
[2] Gao S, Hu M. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem 2010; 10:550-67; PMID:20370701; http://dx.doi.org/10.2174/138955710791384081 [PMC free article] [PubMed] [Cross Ref]
[3] Panossian A, Hovhannisyan A, Mamikonyan G, Abrahamian H, Hambardzumyan E, Gabrielian E, Goukasova G, Wikman G, Wagner H. Pharmacokinetic and oral bioavailability of andrographolide from andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine: International Journal of phytotherapy and phytopharmacology 2000; 7:351-64; PMID:11081986; http://dx.doi.org/10.1016/S0944-7113(00)80054-9 [PubMed] [Cross Ref]
[4] Chen HW, Huang CS, Li CC, Lin AH, Huang YJ, Wang TS, Yao HT, Lii CK. Bioavailability of andrographolide and protection against carbon tetrachloride-induced oxidative damage in rats. Toxicol Appl Pharm 2014; 280:1-9; PMID:NOT_FOUND; http://dx.doi.org/10.1016/j.taap.2014.07.024 [PubMed] [Cross Ref]
[5] Rajagopal S, Kumar RA, Deevi DS, Satyanarayana C, Rajagopalan R. Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J Exp Ther Oncol 2003; 3:147-58; PMID:14641821; http://dx.doi.org/10.1046/j.1359-4117.2003.01090.x [PubMed] [Cross Ref]
[6] Hung SK, Hung LC, Kuo CD, Lee KY, Lee MS, Lin HY, Chen YJ, Fu SL. Andrographolide sensitizes ras-transformed cells to radiation in vitro and in vivo. Int J Radiat Oncol Biol Phys 2010; 77:1232-9; PMID:20610044; http://dx.doi.org/10.1016/j.ijrobp.2010.01.007 [PubMed] [Cross Ref]
[7] Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J: Off Pub FedAm Soc Exp Biol 2004; 18:1240-2; PMID:15180966 [PubMed]
[8] Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol: Off JEur Soci Med Oncol / ESMO 2004; 15:613-7; PMID:NOT_FOUND; http://dx.doi.org/10.1093/annonc/mdh136 [PubMed] [Cross Ref]
[9] Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics 2013; 3:26-33; PMID:23382783; http://dx.doi.org/10.7150/thno.4922 [PMC free article] [PubMed] [Cross Ref]
[10] Singh S, Singh R, Singh UP, Rai SN, Novakovic KR, Chung LW, Didier PJ, Grizzle WE, Lillard JW Jr. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer J Int du Cancer 2009; 125:2288-95; PMID:19610059; http://dx.doi.org/10.1002/ijc.24574 [PMC free article] [PubMed] [Cross Ref]
[11] Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW Jr. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res: Off J Am Assoc Cancer Res 2004; 10:8743-50; PMID:15623660; http://dx.doi.org/CCR-04-026610.1158/1078-0432. [PubMed] [Cross Ref]
[12] Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004; 64:4693-8; PMID:15256432; http://dx.doi.org/10.1158/0008-5472.CAN-03-3437 [PubMed] [Cross Ref]
[13] Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr-Relat Cancer 2009; 16:663-73; PMID:19556286; http://dx.doi.org/10.1677/ERC-09-0109 [PubMed] [Cross Ref]
[14] Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-6; PMID:11242036; http://dx.doi.org/10.1038/35065016 [PubMed] [Cross Ref]
[15] Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin J, Huang J, Qiu F. Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer 2014; 14:49; PMID:24475985; http://dx.doi.org/2407-14-4910.1186/1471- [PMC free article] [PubMed] [Cross Ref]
[16] Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 2006; 79:639-51; PMID:16478915; http://dx.doi.org/10.1189/jlb.1105633 [PubMed] [Cross Ref]
[17] Singh R, Stockard CR, Grizzle WE, Lillard JW Jr., Singh S. Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer. Int J Oncol 2011; 39:373-81; PMID:21637913 [PMC free article] [PubMed]
[18] Neogy S, Das S, Mahapatra SK, Mandal N, Roy S. Amelioratory effect of andrographis paniculata nees on liver, kidney, heart, lung and spleen during nicotine induced oxidative stress. Environ Toxicol Pharmacol 2008; 25:321-8; PMID:21783869; http://dx.doi.org/10.1016/j.etap.2007.10.034 [PubMed] [Cross Ref]
[19] Singha PK., Roy S., Dey S. Protective activity of andrographolide and arabinogalactan proteins from Andrographis paniculata Nees. against ethanol-induced toxicity in mice. J Ethnopharmacol 2007; 111:13–21. [PubMed]
[20] Shi M-D, Lin H-H, Lee Y-C, Chao J-K, Lin R-A, Chen J-H. Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide. Chemico-Biological Interactions 2008; 174:201-10; PMID:18619950; http://dx.doi.org/10.1016/j.cbi.2008.06.006 [PubMed] [Cross Ref]
[21] Yan J, Chen Y, Fau - He C, He C Fau - Yang Z-Z, Yang ZZ Fau - Lu C, Lu C Fau - Chen X-S, Chen XS Andrographolide induces cell cycle arrest and apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes. [PubMed]
[22] Gudas JM, Payton M, Thukral S, Chen E, Bass M, Robinson MO, Coats S. Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol 1999; 19:612-22; PMID:9858585; http://dx.doi.org/10.1128/MCB.19.1.612 [PMC free article] [PubMed] [Cross Ref]
[23] Tung YT, Chen HL, Tsai HC, Yang SH, Chang YC, Chen CM. Therapeutic potential of andrographolide isolated from the leaves of andrographis paniculata nees for treating lung adenocarcinomas. Evidence-based Complementary and Alternative medicine : eCAM 2013; 2013:305898; PMID:23997793 [PMC free article] [PubMed]
[24] Wang LJ, Zhou X, Wang W, Tang F, Qi CL, Yang X, Wu S, Lin YQ, Wang JT, Geng JG. Andrographolide inhibits oral squamous cell carcinogenesis through NF-kappaB inactivation. J Dent Res 2011; 90:1246-52; PMID:21841043; http://dx.doi.org/10.1177/0022034511418341 [PubMed] [Cross Ref]
[25] Tapia-Rojas C, Schuller A, Lindsay CB, Ureta RC, Mejias-Reyes C, Hancke J, Melo F, Inestrosa NC. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3beta: autoregulation of GSK-3beta in vivo. Biochem J 2015; 466:415-30; PMID:25423492; http://dx.doi.org/10.1042/BJ20140207 [PubMed] [Cross Ref]
[26] Woo RA, Poon RY. Cyclin-dependent kinases and S phase control in mammalian cells. Cell cycle (Georgetown, Tex) 2003; 2:316-24; PMID:12851482; http://dx.doi.org/10.4161/cc.2.4.468 [PubMed] [Cross Ref]
[27] Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A. Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 1996; 56:4159-63; PMID:8797586 [PubMed]
[28] Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Nat Acad SciU S A 1995; 92:5386-90; PMID:7539916; http://dx.doi.org/10.1073/pnas.92.12.5386 [PubMed] [Cross Ref]
[29] Egloff AM, Weissfeld J, Land SR, Finn OJ. Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer. AnnNew York Acad Sci 2005; 1062:29-40; PMID:16461786; http://dx.doi.org/10.1196/annals.1358.005 [PubMed] [Cross Ref]
[30] Hagting A, Jackman M Fau - Simpson K, Simpson K Fau - Pines J, Pines J Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal. [PubMed]
[31] Ornelas IM, Silva TM, Fragel-Madeira L, Ventura ALM. Inhibition of PI3K/Akt pathway impairs G2/M transition of cell cycle in late developing progenitors of the avian embryo retina. PloS one 2013; 8:e53517; PMID:23301080; http://dx.doi.org/10.1371/journal.pone.0053517 [PMC free article] [PubMed] [Cross Ref]
[32] Li Y, Zhang P, Qiu F, Chen L, Miao C, Li J, Xiao W, Ma E. Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G2/M phase arrest induced by andrographolide in human glioblastoma cells. Life Sci 2012; 90:962-7; PMID:AMBIGUOUS; http://dx.doi.org/10.1016/j.lfs.2012.04.044 [PubMed] [Cross Ref]
[33] Gong D, Ferrell JE. The Roles of Cyclin A2, B1, and B2 in Early and Late Mitotic Events. Mol Biol Cell 2010; 21:3149-61; PMID:20660152; http://dx.doi.org/10.1091/mbc.E10-05-0393 [PMC free article] [PubMed] [Cross Ref]
[34] Fung TK, Ma HT, Poon RY. Specialized roles of the two mitotic cyclins in somatic cells: cyclin A as an activator of M phase-promoting factor. Mol Biol Cell 2007; 18:1861-73; PMID:17344473; http://dx.doi.org/10.1091/mbc.E06-12-1092 [PMC free article] [PubMed] [Cross Ref]
[35] Hsieh CY., Hsu MJ., Hsiao G., Wang YH., Huang CW., Chen SW., Jayakumar T., Chiu PT., Chiu YH., Sheu JR. Andrographolide enhances nuclear factor-kappaB subunit p65 Ser536 dephosphorylation through activation of protein phosphatase 2A in vascular smooth muscle cells. J Biol Chem 2011; 286:5942–55. [PMC free article] [PubMed]
[36] Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO reports 2003; 4:671-7; PMID:12835754; http://dx.doi.org/10.1038/sj.embor.embor887 [PubMed] [Cross Ref]
[37] Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 1995; 80:225-36; PMID:7834742; http://dx.doi.org/10.1016/0092-8674(95)90405-0 [PubMed] [Cross Ref]
[38] Atherton-Fessler S, Liu F, Gabrielli B, Lee MS, Peng CY, Piwnica-Worms H. Cell cycle regulation of the p34cdc2 inhibitory kinases. Mol Biol Cell 1994; 5:989-1001; PMID:7841526; http://dx.doi.org/10.1091/mbc.5.9.989 [PMC free article] [PubMed] [Cross Ref]
[39] Duronio RJ. Developing S-phase control. Genes Dev 2012; 26:746-50; PMID:22508722; http://dx.doi.org/10.1101/gad.191171.112 [PubMed] [Cross Ref]
[40] Liu G., Lozano G. p21 stability: linking chaperones to a cell cycle checkpoint. Cancer Cell 2005; 7:113–4. [PubMed]
[41] Liu C., Nadiminty N., Tummala R., Chun JY., Lou W., Zhu Y., Sun M., Evans CP., Zhou Q., Gao AC. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer 2011; 2:151–9. [PMC free article] [PubMed]
[42] Liu SH., Lin CH., Liang FP., Chen PF., Kuo CD., Alam MM., Maiti B., Hung SK., Chi CW., Sun CM, et al. Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochem Pharmacol 2014; 87:229–42. [PubMed]
[43] Cialfi S., Palermo R., Manca S., De Blasio C., Vargas Romero P., Checquolo S., Bellavia D., Uccelletti D., Saliola M., D'Alessandro A, et al. Loss of Notch1-dependent p21(Waf1/Cip1) expression influences the Notch1 outcome in tumorigenesis. Cell Cycle 2014; 13:2046–55. [PMC free article] [PubMed]
[44] Aksoy MO, Yang Y, Ji R, Reddy PJ, Shahabuddin S, Litvin J, Rogers TJ, Kelsen SG. CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. Am J Physiol Lung Cell Mol Physiol 2006; 290:L909-18; PMID:16339779; http://dx.doi.org/10.1152/ajplung.00430.2005 [PubMed] [Cross Ref]
[45] Rani MR, Foster GR, Leung S, Leaman D, Stark GR, Ransohoff RM. Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 1996; 271:22878-84; PMID:8798467; http://dx.doi.org/10.1074/jbc.271.37.22878 [PubMed] [Cross Ref]
[46] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65:55-63; PMID:6606682; http://dx.doi.org/10.1016/0022-1759(83)90303-4 [PubMed] [Cross Ref]

Articles from Cell Cycle are provided here courtesy of Taylor & Francis